Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2018

  • ID: 4576049
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 4
Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2018, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.

Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care.

Report Highlights:

This latest pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Report Coverage

Globoid Cell Leukodystrophy (Krabbe Disease) - Overview

Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development

Commence Bio Inc

Kyorin Pharmaceutical Co Ltd

Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profiles

DUOC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGTA-456 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RND-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Globoid Cell Leukodystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects

Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products

Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones

Featured News & Press Releases

Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease

Jun 03, 2015: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Commence Bio Inc, H1 2018

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, H1 2018

Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Commence Bio Inc
  • Kyorin Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll